Single Cell Genome Sequencing Market is Anticipated to Witness High Growth Owing to Increasing Application in Cancer Research
Single Cell Genome Sequencing Market |
Single cell genome sequencing involves isolating
single cells and analyzing the genome of each cell separately. It has gained
prominence in recent years due to its ability to study cellular heterogeneity
at an unprecedented resolution. Single cell sequencing helps to identify rare
cell types and trace cell lineage decisions during development, disease onset
and response to therapy. It has wide application in cancer research for
understanding tumor evolution, detecting circulating tumor cells and
deciphering intra-tumor heterogeneity. Other key applications of single cell
sequencing include neurobiology, immunology and stem cell research.
The Global Single Cell Genome Sequencing
Market is estimated to be valued at US$ 2.63 Bn in 2024 and is expected to
exhibit a CAGR of 3.9% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the single cell genome sequencing are Logitech
International SA, Microsoft Corporation, Datadesk Technologies, Inc., Fentek
Industries Inc., Adesso AG, Shenzhen V4 Electronic Co., Ltd., Fellowes Limited,
Kinesis Corporation, Gold Touch Enterprise Inc., and Posturite UK Ltd. Rapidly
declining costs of sequencing is encouraging adoption by research institutes
and pharmaceutical companies. Technological advancements have enabled analysis
of thousands of cells in parallel, improving throughput and discovery
potential.
Major companies are focusing on geographical expansion to tap Single
Cell Genome Sequencing Market Growth opportunities in emerging markets.
For instance, 10x Genomics recently opened facilities in Belgium and China.
Fluigent launched its microfluidic platform in India in 2020. Such initiatives
will help make single cell analyses accessible to global research communities.
Rising cancer incidence, increasing R&D investments in immunology and
growing stem cell therapies market are expected to drive the demand for single
cell genome sequencing. Growing application scope in prenatal diagnosis and
non-invasive prenatal testing using cell-free DNA analysis from maternal blood
is opening new avenues.
Market Drivers
Declining cost of sequencing: Continuous reductions in the cost of sequencing
equipment and consumables is increasing the affordability of single cell
sequencing experiments. This key driver is expected to boost adoption in
research as well as clinical settings.
Technological advances: Introduction of microfluidic platforms, droplet-based
workflows and automation solutions have enhanced throughput, reproducibility
and analysis potential. This is a major factor contributing to market growth.
Market Restrain
Complexity of workflow: Isolating viable single cells and preparing
representative sequencing libraries requires specialized expertise and
infrastructure. Technical challenges related to whole genome amplification add
to the complexity. This restrain limits widespread adoption.
Lack of standardization: Absence of standardized protocols and quality control
measures hinders multi-center clinical trials and collaborative research
involving data from different sources. It poses challenges for translation into
clinical practice.
Comments
Post a Comment